Why the study?
Does recombinant angioarrestin inhibit primary melanoma tumour growth in a mouse model?
Does recombinant angioarrestin inhibit primary melanoma tumour growth in a mouse model?
Recombinant angioarrestin demonstrates anti-angiogenic properties and inhibits primary melanoma tumour growth in a mouse model.
Answers are grounded in this paper and cite their sources.
Angioarrestin slows melanoma xenograft growth via endothelial inhibition in mice; leaves open any therapeutic role in patients.
Angioarrestin is a recently described anti-angiogenic protein whose expression is down-regulated in solid tumours of various origins. It has a sequence identical to angiopoietin related protein-1. In this study we investigated anti-tumour properties of angioarrestin in B16 (F10) melanoma tumour model. We constructed an expression vector encoding human angioarrestin under the control of EF-1alpha promoter. This vector was transferred to B16 (F10) cells and recombinant angioarrestin secreted from the transfected cells was tested for anti-angiogenic activity using endothelial cell proliferation assay. Finally, mice were injected subcutaneously with cells that had been transfected with either angioarrestin-encoding vector or empty vector and tumor growth was compared. The obtained recombinant angioarrestin inhibited proliferation of bovine aortic endothelial cells. Tumours derived from an angioarrestin-secreting B16 (F10) cell clone grew in vivo more slowly than tumours derived from a cell clone transfected with empty vector. These data show, to our knowledge for the first time, that angioarrestin can inhibit primary melanoma tumour growth.
No takes yet. Share an insight, caveat, or question.
Smagur et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: